Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: Prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.

Journal of Urology

Volumn 167, Issue 1, 2002, Pages 103-111

  Stamey, Thomas A ^a   Johnstone, Iain M ^b   McNeal, John E ^b   Lu, Arthur Y ^b   Yemoto, Cheryl M ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Prostate; Prostate specific antigen; Prostatectomy; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER REGRESSION; CORRELATION FUNCTION; DIAGNOSTIC ERROR; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; TUMOR VOLUME;

EID: 0036136758     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65392-X     Document Type: Article

References (39)

1. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
2. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
3. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
4. Tumor volume and prostate specific antigen: Implications for early detection and defining a window of curability
5. Limitations of serum PSA in predicting peripheral and transition zone cancer volume as measured by correlation coefficients
6. Biologic determinants of cancer progression in men with prostate cancer
7. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate
8. Prostate specific antigen and Gleason grade: An immunohistochemical study of prostate cancer
9. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less
10. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements
11. Histological and clinical findings in 896 consecutive prostates treated only by radical retropubic prostatectomy from 1988 to 1997: Epidemiologic significance of annual changes
12. Capsular penetration in prostate cancer: Significance for natural history and treatment
13. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate
14. The zonal anatomy of the prostate in man and in the rhesus monkey (Macaca mulatta)
15. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: Common ground for therapeutic trials and TNM subgroups
16. Local regression models
17. "Dummy" variables
18. Confidence intervals based on bootstrap percentiles
19. An analysis of 148 consecutive transition zone cancers: Clinical and histological characteristics
20. Serum PSA and the biologic progression of prostate cancer
21. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia
22. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia
23. Examination of the 3 molecular forms of serum PSA in distinguishing biopsy-negative from biopsy-positive men: Relationship to transition zone volume
24. The use of prostate specific antigen density to enhance the predictive value of inter-mediate levels of serum prostate specific antigen
25. Effect of ageing on morphologic and clinical predictors of prostate cancer progression
26. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies
27. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease
28. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
29. Physiological variation of serum prostate specific antigen (PSA) in the 4.0-10.0 ng/ml range in male volunteers
30. Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
31. Prostate-specific antigen as predictor of prostate cancer in black and white men
32. Characteristics of screening detected prostate cancer in men 50 to 66-year-old with 3 to 4 ng/ml prostate specific antigen
33. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers
34. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer
35. Editorial comment
36. Early detection of prostate cancer. Serendipity strikes again
37. Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates
38. Relationship between systematic biopsies and histologic features in 222 radical prostatectomy specimens: Lack of prediction of tumor significance in men with nonpalpable prostate cancer
39. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen